Connection lost
Server error
Schering Corp. v. Geneva Pharmaceuticals, Inc. Case Brief
Why Top Law Students (And Those Aspiring to Be) Use LSD+ Briefs
Let's be real, law school is a marathon. Our exclusive Flash-to-Full case system is designed by Harvard Law School and MIT grads to match your pace: Quick summaries when you're slammed, detailed analysis when you need to go deep. Only LSD+ offers this kind of flexibility to genuinely fit your study flow.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: The court invalidated a patent for a drug metabolite, finding it was inherently anticipated by a prior patent for the parent drug. Ingesting the parent drug, as taught by the prior art, necessarily and inevitably produces the metabolite, even if its existence was previously unknown.
Legal Significance: Established that a prior art reference can inherently anticipate an entire claimed invention, not just a single limitation, even if the invention’s existence was unrecognized at the time. Recognition of the inherent feature is not required for anticipation under 35 U.S.C. § 102.
Schering Corp. v. Geneva Pharmaceuticals, Inc. Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Schering Corporation owned U.S. Patent No. 4,282,233 (‘233 patent), which covered the non-drowsy antihistamine loratadine (marketed as Claritin). After the ‘233 patent was issued, Schering obtained U.S. Patent No. 4,659,716 (‘716 patent), which claimed descarboethoxyloratadine (DCL), a metabolite of loratadine. A metabolite is a compound formed within the body after a drug is ingested. The ‘233 patent disclosed loratadine and its administration to patients but did not expressly mention DCL or any other metabolites. Because the ‘233 patent was issued more than one year before the ‘716 patent’s application, it qualified as prior art under 35 U.S.C. § 102(b). When Geneva Pharmaceuticals and other companies sought to market generic loratadine, they challenged the validity of the ‘716 patent. The district court granted summary judgment for the generic manufacturers, finding the ‘716 patent claims for the DCL compound were inherently anticipated by the ‘233 patent. Undisputed evidence showed that administering loratadine to a human, as taught by the ‘233 patent, necessarily and inevitably results in the formation of DCL. Schering appealed, arguing that anticipation by inherency requires prior recognition of the inherent feature.
Court Holding & Legal Precedent
Issue: Does a prior art patent that discloses a compound and its administration inherently anticipate a later patent claiming a metabolite that is necessarily and inevitably formed upon administration of the original compound, even if the metabolite was not expressly disclosed or recognized in the prior art?
Yes, the patent claims for the metabolite DCL are invalid as inherently Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
IRAC Legal Analysis
Complete IRAC Analysis for Higher Grades
IRAC (Issue, Rule, Analysis, Conclusion) is the exact format professors want to see in your exam answers. Our exclusive Flash-to-Full briefs combine holding, analysis, and rule statements formatted to match what A+ students produce in exams. These structured briefs help reinforce the essential legal reasoning patterns expected in law school.
Legal Issue
Does a prior art patent that discloses a compound and its administration inherently anticipate a later patent claiming a metabolite that is necessarily and inevitably formed upon administration of the original compound, even if the metabolite was not expressly disclosed or recognized in the prior art?
Conclusion
This case establishes that an unknown but necessary and inevitable result of Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
Legal Rule
A patent claim is anticipated under 35 U.S.C. § 102 if a Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt moll
Legal Analysis
The Federal Circuit affirmed the district court's summary judgment of invalidity, establishing Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
Flash-to-Full Case Opinions
Flash Summary
- A prior art patent disclosing a drug (loratadine) inherently anticipates a